Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $31.5 million.

  • Trinity Biotech's Total Current Liabilities rose 2232.44% to $31.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $31.5 million, marking a year-over-year increase of 2232.44%. This contributed to the annual value of $32.1 million for FY2024, which is 11346.86% up from last year.
  • Trinity Biotech's Total Current Liabilities amounted to $31.5 million in Q2 2025, which was up 2232.44% from $32.1 million recorded in Q4 2024.
  • In the past 5 years, Trinity Biotech's Total Current Liabilities ranged from a high of $105.6 million in Q2 2021 and a low of $12.7 million during Q3 2023
  • Its 5-year average for Total Current Liabilities is $35.4 million, with a median of $22.8 million in 2024.
  • As far as peak fluctuations go, Trinity Biotech's Total Current Liabilities surged by 36426.81% in 2021, and later plummeted by 8685.77% in 2022.
  • Trinity Biotech's Total Current Liabilities (Quarter) stood at $100.5 million in 2021, then tumbled by 82.75% to $17.3 million in 2022, then decreased by 13.29% to $15.0 million in 2023, then soared by 113.47% to $32.1 million in 2024, then decreased by 1.78% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q2 2025, $32.1 million for Q4 2024, and $28.1 million during Q3 2024.